Top

Gepubliceerd in:

17-05-2021

The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia

Auteurs: Ingrid A. Cox, Barbara de Graaff, Hasnat Ahmed, Julie Campbell, Petr Otahal, Tamera J. Corte, Ian Glaspole, Yuben Moodley, Nicole Goh, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

Gepubliceerd in: Quality of Life Research | Uitgave 9/2021

Abstract

Purpose

Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs.

Methods

Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension—five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query

Results

A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from − 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61–0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities.

Conclusions

Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.

vorige artikel Association between knee symptoms, change in knee symptoms over 6–9 years, and SF-6D health state utility among middle-aged Australians

volgende artikel Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness

Alleen toegankelijk voor geautoriseerde gebruikers

Richeldi, L., Collard, H. R., & Jones, M. G. (2017). Idiopathic pulmonary fibrosis. The Lancet, 389(10082), 1941–1952. https://doi.org/10.1016/s0140-6736(17)30866-8.CrossRef

Swigris, J. J., & Fairclough, D. (2012). Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest, 142(2), 291–297. https://doi.org/10.1378/chest.11-2602.CrossRefPubMedPubMedCentral

Cox, I. A., Arriagada, N. B., de Graaff, B., Corte, T. J., Glaspole, I., Lartey, S., Walters, E. H., & Palmer, A. J. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. European Respiratory Review, 29(158), 200154. https://doi.org/10.1183/16000617.0154-2020.CrossRefPubMed

York Health Economics Consortium (2016). Preference based measures. hhttps://yhec.co.uk/glossary/preference-based-measures/. Accessed 5 Oct 2020.

Drug Utilisation Sub-committee PBAC (2020). Nintedanib and pirfenidone: 24 month predicted versus actual analysis. Canberra, Australia: Pharmaceutical Benefits Scheme, Commonwealth Department of Health, Government of Australia. https://www.pbs.gov.au/pbs/industry/listing/participants/public-release-docs/2020-02/nintedanib-and-pirfenidone-24-month-predicted-versusactual. Accessed 10 July 2020.

EuroQol Research Foundation (2020). EQ-5D-5L about. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/. Accessed 20 Jun 2020.

Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics, 21(8), 1245–1257. https://doi.org/10.1007/s10198-020-01195-8.CrossRefPubMedPubMedCentral

Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., & Allan, H. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 02. https://doi.org/10.1183/13993003.01592-2016.CrossRef

Moodley, Y., Goh, N., Glaspole, I., Macansh, S., Walters, E. H., Chapman, S., et al. (2014). Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative project. Respirology, 19(7), 1088–1091. https://doi.org/10.1111/resp.12358.CrossRefPubMed

10.

Kolb, M., & Collard, H. R. (2014). Staging of idiopathic pulmonary fibrosis: Past, present and future. European Respiratory Reviews, 23(132), 220–224. https://doi.org/10.1183/09059180.00002114.CrossRef

11.

Puxeddu, E., & Rogliani, P. (2016). Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World Journal of Respirology. https://doi.org/10.5320/wjr.v6.i1.14.CrossRef

12.

Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., & King, T. E., Jr. (2012). A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine, 156(10), 684–695. https://doi.org/10.7326/0003-4819-156-10-201205150-00004.CrossRefPubMed

13.

Jo, H. E., Glaspole, I., Moodley, Y., Chapman, S., Ellis, S., Goh, N., Hopkins, P., Keir, G., Mahar, A., Cooper, W., & Reynolds, P. (2018). Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: Analysis from the Australian IPF registry. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-018-0575-y.CrossRefPubMedPubMedCentral

14.

Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S., Cramer, D., Nicholson, A. G., Colby, T. V., Du Bois, R. M., & Hansell, D. M. (2013). Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. American Journal of Respiratory and Critical Care Medicine, 167(7), 962–969. https://doi.org/10.1164/rccm.2111053.CrossRef

15.

Erbes, R., Schaberg, T., & Loddenkemper, R. (1997). Lung function tests in patients with idiopathic pulmonary fibrosis: Are they helpful for predicting outcome? Chest, 111(1), 51–57. https://doi.org/10.1378/chest.111.1.51.CrossRefPubMed

16.

Lopes, A. J., Capone, D., Mogami, R., Lanzillotti, R. S., Melo, PLd., & Jansen, J. M. (2011). Severity classification for idiopathic pulmonary fibrosis by using fuzzy logic. Clinics, 66(6), 1015–1019. https://doi.org/10.1590/s1807-59322011000600016.CrossRefPubMedPubMedCentral

17.

EuroQol Research Foundation (2020). EQ-5D-3L about. hhttps://euroqol.org/eq-5d-instruments/eq-5d-3l-about/. Accessed 15 Nov 2020.

18.

R Core Team. (2019). R: A language and environment for statistical computing. (3.5.1). Vienna: R Foundation for Statistical Computing.

19.

Morton, F., & Nijjar, J. S. (2019). “eq5d” package: Methods for Analysing ‘EQ-5D’ Data and Calculating ‘EQ-5D’ Index Scores. https://cran.r-project.org/web/packages/eq5d/index.html. Accessed June 20 2020.

20.

StataCorp. (2019). Stata statistical software: Release 16. Texas: StataCorp LLC.

21.

EuroQol Research Foundation (2020). EQ-5D-5L valuation: Standard value sets. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standardvalue-sets/. Accessed 5 Oct 2020.

22.

Norman, R., Cronin, P., & Viney, R. (2013). A pilot discrete choice experiment to explore preferences for EQ-5D-5L Health states. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-013-0035-z.CrossRefPubMed

23.

Van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., Lloyd, A., Scalone, L., Kind, P., & Pickard, A. S. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–715. https://doi.org/10.1016/j.jval.2012.02.008.CrossRefPubMed

24.

EuroQol Research Foundation (2019). EQ-5D-5L Valuation Crosswalk Index Value Calculator. https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/. Accessed 5 Oct 2020.

25.

EuroQol Research Foundation (2019). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/. Accessed 5 Oct 2020.

26.

Jo, H. E., Troy, L. K., Keir, G., Chambers, D. C., Holland, A., Goh, N., Wilsher, M., De Boer, S., Moodley, Y., Grainge, C., & Whitford, H. (2017). Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 22(7), 1436–1458. https://doi.org/10.1111/resp.13146.CrossRefPubMed

27.

Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., & Johkoh, T. (2015). An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 192(2), e3–e19. https://doi.org/10.1164/rccm.201506-1063ST.CrossRefPubMed

28.

Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., & Flaherty, K. R. (2018). Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. American Journal of Respiratory and Critical Care Medicine, 198(5), e44–e68. https://doi.org/10.1164/rccm.201807-1255ST.CrossRefPubMed

29.

Akgun, K. M., Crothers, K., & Pisani, M. (2012). Epidemiology and management of common pulmonary diseases in older persons. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences., 67(3), 276–91. https://doi.org/10.1093/gerona/glr251.CrossRef

30.

Nolan, C. M., Longworth, L., Lord, J., Canavan, J. L., Jones, S. E., Kon, S. S., & Man, W. D. (2016). The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference. Thorax, 71(6), 493. https://doi.org/10.1136/thoraxjnl-2015-207782.CrossRefPubMed

31.

Dowman, L. M., McDonald, C. F., Hill, C. J., Lee, A. L., Barker, K., Boote, C., Glaspole, I., Goh, N. S. L., Southcott, A. M., Burge, A. T., Gillies, R., Martin, A., & Holland, A. E. (2017). The evidence of benefits of exercise training in interstitial lung disease: A randomised controlled trial. Thorax, 72(7), 610–619. https://doi.org/10.1136/thoraxjnl-2016-208638.CrossRefPubMed

32.

Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956. https://doi.org/10.1111/resp.12989.CrossRefPubMed

33.

Corte, T., Bonella, F., Crestani, B., Demedts, M. G., Richeldi, L., Coeck, C., Pelling, K., Quaresma, M., & Lasky, J. A. (2015). Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 16, 116–116. https://doi.org/10.1186/s12931-015-0276-5.CrossRefPubMedPubMedCentral

34.

King, T. E., Jr., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stahler, G., Leconte, I., Roux, S., & Raghu, G. (2008). BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 177(1), 75–81.CrossRef

35.

King, T. E., Jr., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., & Behr, J. (2011). BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 184(1), 92–99. https://doi.org/10.1164/rccm.201011-1874OC.CrossRef

36.

Kolb, M., Raghu, G., Wells, A. U., Behr, J., Richeldi, L., Schinzel, B., Quaresma, M., Stowasser, S., & Martinez, F. J. (2018). Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1811737.CrossRef

37.

Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., Botteman, M., & Busschbach, J. (2017). Mapping to estimate health-state utility from non–preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20(1), 18–27. https://doi.org/10.1016/j.jval.2016.11.006.CrossRefPubMed

38.

Caminati, A., Cassandro, R., Torre, O., & Harari, S. (2017). Severe idiopathic pulmonary fibrosis: What can be done? European Respiratory Review. https://doi.org/10.1183/16000617.0047-2017.CrossRefPubMed

39.

Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T.,…Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139. https://doi.org/10.1186/s12931-017-0621-y.CrossRefPubMedPubMedCentral

40.

Szentes, B. L., Kreuter, M., Bahmer, T., Birring, S. S., Claussen, M., Waelscher, J., Leidl, R., & Schwarzkopf, L. (2018). Quality of life assessment in interstitial lung diseases: A comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respiratory Research. https://doi.org/10.1186/s12931-018-0808-x.CrossRefPubMedPubMedCentral

41.

Case, A. H., Hellkamp, A. S., Neely, M. L., Bender, S., Dilling, D. F., Gulati, M., Hotchkin, D. L., Huie, T. J., Lancaster, L., Snyder, L. D., Conoscenti, C. S., & Palmer, S. M. (2020). Associations between patient-reported outcomes and death or lung transplant in IPF: Data from the IPF-PRO registry. Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.201906-437OC.CrossRefPubMedPubMedCentral

42.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez, F. J., de Andrade, J. A., Anstrom, K. J., King, T. E., Jr., & Raghu, G. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine, 370(22), 2093–2101. https://doi.org/10.1056/NEJMoa1401739.CrossRef

43.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman, D. A., Schwarz, M., Anstrom, K. J., Collard, H. R., Flaherty, K. R., & Hunninghake, G. W. (2010). A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. New England Journal of Medicine, 363(7), 620–628. https://doi.org/10.1056/NEJMoa1002110.CrossRef

44.

Noth, I., Anstrom, K. J., Calvert, S. B., De Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., Olman, M. A., & Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). (2012). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 186(1), 88–95. https://doi.org/10.1164/rccm.201202-0314OC.CrossRefPubMedPubMedCentral

45.

O’Brien, E. C., Hellkamp, A. S., Neely, M. L., Swaminathan, A., Bender, S., Snyder, L. D., Culver, D. A., Conoscenti, C. S., Todd, J. L., Palmer, S. M., Leonard, T. B., & IPF-PRO Registry investigators. (2020). Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: A cross-sectional analysis of the IPF-PRO registry. Chest. https://doi.org/10.1016/j.chest.2019.11.042.CrossRefPubMed

46.

Bloem, A. E. M., Mostard, R. L. M., Stoot, N., Vercoulen, J. H., Peters, J. B., Janssen, D. J. A., Custers, J. W., & Spruit, M. A. (2020). Severe fatigue is highly prevalent in patients with IPF or sarcoidosis. Journal of Clinical Medicine, 9(4), 20. https://doi.org/10.3390/jcm9041178.CrossRef

47.

Moor, C., Kimman, M. L., van Manen, M. J. G., Dirksen, C. D., Wijsenbeek, M. S., & Van Jaarsveld, F. X. (2017). Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis. European Respiratory Journal, 50(suppl 61), PA4884. https://doi.org/10.1183/1393003.congress-2017.PA4884.CrossRef

48.

Wapenaar, M., Patel, A. S., Birring, S. S., et al. (2017). Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 14(2), 140–150.CrossRef

49.

McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016). Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health and Quality of Life Outcomes, 14(1), 133. https://doi.org/10.1186/s12955-016-0537-0.CrossRefPubMedPubMedCentral

50.

Center for the evaluation of value and risk in health the cost-effectiveness analysis registry. https://www.cearegistry.org. Accessed 5 Oct 2020.

51.

Nafees, B., Lloyd, A. J., Dewilde, S., Rajan, N., & Lorenzo, M. (2017). Health state utilities in non-small cell lung cancer: An international study. Asia-Pacific Journal of Clinical Oncology, 13(5), e195–e203. https://doi.org/10.1111/ajco.12477.CrossRefPubMed

52.

McClure, N. S., Sayah, F. A., Xie, F., Luo, N., & Johnson, J. A. (2017). Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value in Health, 20(4), 644–650. https://doi.org/10.1016/j.jval.2016.11.015.CrossRefPubMed

53.

Payakachat, N., Ali, M. M., & Tilford, J. M. (2015). Can the EQ-5D detect meaningful change? A systematic review. Pharmacoeconomics, 33(11), 1137–1154. https://doi.org/10.1007/s40273-015-0295-6.CrossRefPubMedPubMedCentral

54.

Hyldgaard, C., Hilberg, O., & Bendstrup, E. (2014). How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respiratory Medicine, 108(4), 647–653. https://doi.org/10.1016/j.rmed.2014.01.008.CrossRefPubMed

55.

Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015). Mechanisms of human autoimmunity. The Journal of Clinical Investigation, 125(6), 2228–2233. https://doi.org/10.1172/JCI78088.CrossRefPubMedPubMedCentral

56.

Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018). The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Frontiers in Medicine (Lausanne), 5, 43–43. https://doi.org/10.3389/fmed.2018.00043.CrossRef

57.

Hoyne, G. F., Elliott, H., Mutsaers, S. E., & Prele, C. M. (2017). Idiopathic pulmonary fibrosis and a role for autoimmunity. Immunology & Cell Biology, 95(7), 577–583. https://doi.org/10.1038/icb.2017.22.CrossRef

58.

Caffarelli, C., Gonnelli, S., Tomai Pitinca, M. D., Francolini, V., Fui, A., Bargagli, E., Refini, R. M., Bennett, D., Nuti, R., & Rottoli, P. (2016). Idiopathic pulmonary fibrosis a rare disease with severe bone fragility. Internal and Emergency Medicine, 11(8), 1087–1094. https://doi.org/10.1007/s11739-016-1501-z.CrossRefPubMed

59.

Ikezoe, K., Handa, T., Tanizawa, K., Kubo, T., Oguma, T., Hamada, S., Watanabe, K., Aihara, K., Sokai, A., Nakatsuka, Y., & Muro, S. (2015). Bone mineral density in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 109(9), 1181–1187. https://doi.org/10.1016/j.rmed.2015.06.014.CrossRefPubMed

60.

Peasgood, T., Herrmann, K., & Kanis, J. A. (2009). An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporosis International, 20, 853–868. https://doi.org/10.1007/s00198-009-0844-y.CrossRefPubMed

61.

Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012). Incidence and prevalence of idiopathic pulmonary fibrosis: Review of the literature. European Respiratory Reviews, 21(126), 355–361. https://doi.org/10.1183/09059180.00002512.CrossRef

62.

Australian Bureau of Statistics (2020). Australian demographic statistics, December 2019. https://www.abs.gov.au/Population. Accessed 21 July 2020.

63.

Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics, 27(1), 7–22. https://doi.org/10.1002/hec.3564.CrossRefPubMed

64.

Kim, H. J., Perlman, D., & Tomic, R. (2015). Natural history of idiopathic pulmonary fibrosis. Respiratory Medicine, 109(6), 661–670. https://doi.org/10.1016/j.rmed.2015.02.002.CrossRefPubMed

Titel: The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia
Auteurs: Ingrid A. Cox
Barbara de Graaff
Hasnat Ahmed
Julie Campbell
Petr Otahal
Tamera J. Corte
Ian Glaspole
Yuben Moodley
Nicole Goh
Sacha Macansh
E. Haydn Walters
Andrew J. Palmer
Publicatiedatum: 17-05-2021
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 9/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-021-02879-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2021

Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies

Exercise tolerance and quality of life in patients with known or suspected coronary artery disease

Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy

The relationship between emotional intelligence and quality of life in schizophrenia and bipolar I disorder

Symptom profiles following combat injury and long-term quality of life: a latent class analysis

The association between nonrestorative sleep and health-related quality of life in Chinese adults: a cross-sectional study